Sai Life Sciences Limited has informed the Exchange about Credit Rating- Revision
SAILIFE · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
India Ratings & Research (Fitch Group) has upgraded Sai Life Sciences' long-term bank loan rating from IND A+/Stable to IND AA-/Positive, while affirming the short-term rating at IND A1+. The rated bank loan facility was also reduced from INR 11,800 million to INR 7,690 million. The upgrade is driven by strong FY25 results — revenue grew 16% YoY to INR 16,946 million, EBITDA margin expanded to 23.9% (from 19.5%), and 1QFY26 saw revenue jump 77% YoY. The company significantly deleveraged by prepaying INR 7,200 million in term loans using IPO proceeds raised in December 2024, bringing net leverage to nil. The Positive Outlook signals expectations of further improvement from better capacity utilisation, new molecule contributions, and planned capex of INR 7 billion over FY26-FY27.
Positive for shareholders — the rating upgrade reflects stronger financial health, lower debt risk, and improving profitability, which could lower future borrowing costs and boost investor confidence in the stock.